Skip to main content
. 2023 Jun 24;11(7):1812. doi: 10.3390/biomedicines11071812

Table 2.

Classification of anticonvulsants used in neuropathic pain.

Anticonvulsant Classification Mechanism of Action Recommended Doses in
Monotherapy
Maximum Doses
Gabapentin



Pregabalin
Ion channel modulators (reduce neuronal excitability) Calcium ion channels.
Decreasing the density of pre-synaptic voltage-gated calcium channels and subsequent release of excitatory neurotransmitter
300 mg/day



150 mg/day
3600 mg/day

600 mg/day
Topiramate Multiple mechanisms of action.
increasing GABA activity and inhibiting glutamate activity, topiramate blocks neuronal excitability
Canales de iones sódicos receptores GABAA, NMDA
AMPA/kainato
100–200 mg/day 1000 mg/day
Carbamazepine
Oxcarbazepine


Lamotrigine









Phenytoin
Ion channel modulators (reduce neuronal excitability) Sodium ion channels



Selectively binds and inhibits voltage-gated sodium channels, stabilizing presynaptic neuronal membranes and inhibiting presynaptic glutamate and aspartate release.


Stabilizing the inactive state of the sodium channel and prolonging the neuronal refractory period
100–200 mg/day
600 mg/day

100–200 mg/day


200–400 mg/day
1200 mg/day
2400 mg/day

600–700 mg/day


500–600 mg/day
Levetiracetam Modulators of the presynaptic junction Modulation of synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A in the brain 250 mg/day 1500 mg/day
Clonazepam


Diazepam
GABAergic transmission enhancers (potentiate inhibitory neurotransmission) GABA-A receptors action. 0.5–1 mg/day


5–10 mg/day
2–4 mg/day


15–20 mg/day

GABA, gamma-aminobutyric acid; GABA-A, gamma-aminobutyric acid subunit A. AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid. NMDA, N-methyl-d-aspartate; Sv2A, synaptic vesicle glycoprotein 2A.